(19)
(11) EP 3 390 643 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
02.08.2023 Bulletin 2023/31

(45) Mention of the grant of the patent:
28.06.2023 Bulletin 2023/26

(21) Application number: 16876875.2

(22) Date of filing: 16.12.2016
(51) International Patent Classification (IPC): 
C12N 15/85(2006.01)
C12N 15/63(2006.01)
A61P 35/00(2006.01)
A61K 39/39(2006.01)
 C12N 15/79(2006.01)
C12N 15/09(2006.01)
A61K 48/00(2006.01)
A61K 39/00(2006.01)
(52) Cooperative Patent Classification (CPC):
C07K 14/52; C07K 14/5434; C07K 2319/00; C12N 15/85; A61P 35/00
(86) International application number:
PCT/US2016/067388
(87) International publication number:
WO 2017/106795 (22.06.2017 Gazette 2017/25)

(54)

PLASMID CONSTRUCTS FOR HETEROLOGOUS PROTEIN EXPRESSION AND METHODS OF USE

PLASMIDKONSTRUKTE ZUR HETEROLOGEN PROTEINEXPRESSION UND VERFAHREN ZUR VERWENDUNG

CONSTRUCTIONS PLASMIDIQUES POUR L'EXPRESSION DE PROTÉINES HÉTÉROLOGUES ET LEURS PROCÉDÉS D'UTILISATION

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 18.12.2015 US 201562269702 P
15.08.2016 US 201662375245 P

(43) Date of publication of application:
24.10.2018 Bulletin 2018/43

(73) Proprietor: OncoSec Medical Incorporated
Ewing, NJ 08628 (US)

(72) Inventors:
  • CAMPBELL, Jean
    Poway, CA 92064 (US)
  • CANTON, David A.
    Poway, CA 92064 (US)
  • PIERCE, Robert H.
    San Diego, CA 92101 (US)

(74) Representative: Murgitroyd & Company 
Murgitroyd House 165-169 Scotland Street
Glasgow G5 8PL
Glasgow G5 8PL (GB)


(56) References cited: : 
WO-A1-00/75292
WO-A2-2010/042189
US-A1- 2008 033 340
US-B1- 8 802 643
 WO-A2-2004/035799
US-A- 5 891 432
US-A1- 2011 124 048
   
  • WEN XIAO-YAN ET AL: "Tricistronic viral vectors co-expressing interleukin-12 (IL-12) and CD80 (B7-1) for the immunotherapy of cancer: Preclinical studies in myeloma", CANCER GENE THERAPY, APPLETON & LANGE, GB, vol. 8, no. 5, 1 May 2001 (2001-05-01), pages 361-370, XP002298032, ISSN: 0929-1903, DOI: 10.1038/SJ.CGT.7700321
  • HAJIZADEH-SIKAROODI SHOHREH ET AL: "Lentiviral Mediating Genetic Engineered Mesenchymal Stem Cells for Releasing IL-27 as a Gene Therapy Approach for Autoimmune Diseases", CELL JOURNAL, vol. 16, no. 3, October 2014 (2014-10), pages 255-262, XP002790455,
  • ADIL DAUD ET AL: "Intratumoral electroporation of plasmid interleukin-12: efficacy and biomarker analyses from a phase 2 study in melanoma (OMS-I100)", JOURNAL OF TRANSLATIONAL MEDICINE, BIOMED CENTRAL, vol. 13, no. Suppl 1, 15 January 2015 (2015-01-15), page O11, XP021208151, ISSN: 1479-5876, DOI: 10.1186/1479-5876-13-S1-O11
  • LEE S C ET AL: "Inhibition of established subcutaneous and metastatic murine tumors by intramuscular electroporation of the interleukin-12 gene", JOURNAL OF BIOMEDICAL SCIENCE, KARGER, BASEL, CH, vol. 10, no. 1, 1 February 2003 (2003-02-01), pages 73-86, XP002982809, ISSN: 1021-7770
  • CHAMBERS ROSS S ET AL: "High-level generation of polyclonal antibodies by genetic immunization", NATURE BIOTECHNOLOGY, GALE GROUP INC, NEW YORK, vol. 21, no. 9, 1 September 2003 (2003-09-01), pages 1088-1092, XP002382543, ISSN: 1087-0156, DOI: 10.1038/NBT858
  • YO Y-T ET AL: "Coexpression of Flt3 ligand and GM-CSF genes modulates immune responses induced by HER2/neu DNA vaccine", CANCER GENE THERAPY, vol. 14, no. 11, November 2007 (2007-11), pages 904-917, XP002790456, ISSN: 0929-1903
  • BURGER J A ET AL: "Plasmids encoding granulocyte-macrophage colony-stimulating factor and CD154 enhance the immune response to genetic vaccines", VAC, ELSEVIER, AMSTERDAM, NL, vol. 19, no. 15-16, 28 February 2001 (2001-02-28), pages 2181-2189, XP004316960, ISSN: 0264-410X, DOI: 10.1016/S0264-410X(00)00382-0
  • LLADSER A ET AL: "Naked DNA immunization as an approach to target the generic tumor antigen survivin induces humoral and cellular immune responses in mice", IMMUNOBIOLOGY, URBAN UND FISCHER VERLAG, DE, vol. 211, no. 1-2, 22 February 2006 (2006-02-22), pages 11-27, XP028020185, ISSN: 0171-2985, DOI: 10.1016/J.IMBIO.2005.08.002 [retrieved on 2006-02-22]
  • RIVOLTINI LICIA ET AL: "Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells.", JOURNAL OF IMMUNOLOGY, vol. 171, no. 7, 1 October 2003 (2003-10-01), pages 3467-3474, XP002790457, ISSN: 0022-1767
  • DEAN, DA ET AL.: 'Electrical Impedance Spectroscopy Study of Biological Tissues.' JOURNAL OF ELECTROSTATICS. vol. 66, no. 3-4;, March 2008, pages 165 - 177, XP022510120
  • LIMA, J ET AL.: 'A DNA vaccine encoding genetic fusions of carcinoembryonic antigen (CEA) and granulocyte/macrophage colony-stimulating factor (GM-CSF).' VACCINE vol. 23, no. 10, 26 January 2005, pages 1273 - 1283, XP027651809
  • TENBUSCH, M ET AL.: 'Coexpression of GM-CSF and antigen in DNA prime-adenoviral vector boost immunization enhances polyfunctional CD 8+ T cell responses, whereas expression of GM-CSF antigen fusion protein induces autoimmunity.' BCM IMMUNOLOGY vol. 9, no. 13, 11 April 2008, pages 1 - 15, XP021033204
  • YO Y-T ET AL: "Coexpression of Flt3 ligand and GM-CSF genes modulates immune responses induced by HER2/neu DNA vaccine", CANCER GENE THERAPY, vol. 14, no. 11, November 2007 (2007-11), pages 904-917, ISSN: 0929-1903
  • RIVOLTINI LICIA ET AL: "Human tumor-derived heat shock protein 96 mediates in vitro activation and in vivo expansion of melanoma- and colon carcinoma-specific T cells.", JOURNAL OF IMMUNOLOGY, vol. 171, no. 7, 1 October 2003 (2003-10-01), pages 3467-3474, ISSN: 0022-1767
  • HAJIZADEH-SIKAROODI SHOHREH ET AL: "Lentiviral Mediating Genetic Engineered Mesenchymal Stem Cells for Releasing IL-27 as a Gene Therapy Approach for Autoimmune Diseases", CELL JOURNAL, vol. 16, no. 3, 2014, pages 255-262, ISSN: 2228-5806(print)
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).